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Abstract: Kaposi sarcoma-associated herpesvirus (KSHV) is the causative agent of multiple cancers
in immunocompromised patients including two lymphoproliferative disorders associated with
KSHV infection of B lymphocytes. Despite many years of research into the pathogenesis of KSHV
associated diseases, basic questions related to KSHV molecular virology remain unresolved. One
such unresolved question is the cellular receptors and viral glycoproteins needed for KSHV entry
into primary B lymphocytes. In this study, we assess the contributions of KSHV glycoprotein H
(gH) and the cellular receptor DC-SIGN to KSHV infection in tonsil-derived B lymphocytes. Our
results show that (1) neither KSHV-gH nor DC-SIGN are essential for entry into any B cell subset,
(2) DC-SIGN does play a role in KSHV entry into tonsil-derived B cells, but in all B cell subtypes
alternative entry mechanisms exist, (3) KSHV-gH can participate in KSHV entry into centrocytes
via a DC-SIGN independent entry mechanism, and (4) in the absence of KSHV-gH, DC-SIGN is
required for KSHV entry into centrocytes. Our results provide a first glimpse into the complexity of
KSHV entry in the lymphocyte compartment and highlight that multiple subset-dependent entry
mechanisms are employed by KSHV which depend upon multiple cellular receptors and multiple
KSHV glycoproteins.
Keywords: KSHV; glycoprotein H; lymphotropism; DC-SIGN; viral entry
1. Introduction
Kaposi Sarcoma Herpesvirus (KSHV) is an oncogenic herpesvirus and one of only two
human herpesviruses known to infect B lymphocytes. KSHV lymphotropism results in two
lymphoproliferative disorders, PEL and MCD [1,2]. Despite decades of research related to
KSHV pathogenesis, essential questions remain unanswered related to how KSHV invades
a new human host and particularly how the virus invades the human immune system.
Studies addressing these gaps are particularly critical to inform the rational development
of prophylactic vaccine strategies to limit KSHV transmission.
The highly conserved glycoproteins gB, gH and gL form the canonical core entry
machinery for all herpesviruses, and various additional glycoproteins, which vary between
herpesviruses, work together with these core proteins to mediate the broad cellular tropism
characteristic of human herpesviruses [3]. There is a considerable body of literature
characterizing the cellular receptors and KSHV glycoproteins involved in viral entry
in vitro. However, no study to date has succeeded in completely abrogating KSHV infection
via inhibition of a specific cellular receptor, suggesting that KSHV universally employs
redundant entry mechanisms involving multiple cellular receptors and glycoproteins [4].
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In epithelial, endothelial and fibroblast cell types, KSHV infection is facilitated by
attachment of gB, gH/gL and/or K8.1 to heparin sulfate proteoglycans, however our
recent work showed that HSPG play no role in infection of primary tonsil-derived B
lymphocytes [5]. Similarly, a previous study from our group recently showed that KSHV-
gH is essential for entry into all adherent cell types tested, but is not required for entry into
the MC116 lymphoma cell line [6]. Thus, there is accumulating evidence that KSHV uses
different mechanisms for entry into B cells compared to adherent cells.
DC-SIGN, also known as, Dendritic Cell-Specific ICAM-3-Grabbing Non-integrin,
CD209, is a type II C-type (calcium-dependent) lectin receptor [7] and is highly expressed
in cells of the immune system such as dendritic cells (DCs), in dermal and mucosal
tissues, monocytes, macrophages, B lymphocytes from peripheral blood, and tonsillar
B lymphocytes [8,9]. DC-SIGN plays a critical role in the innate and adaptive immune
response by facilitating immune cell signaling, adhesion and migration [10]. DC-SIGN
is utilized as an entry receptor by many viruses such as Ebola virus, HIV-1, Hepatitis C,
KSHV, SARS coronavirus, and Dengue virus [11]. Studies have demonstrated that KSHV
uses DC-SIGN as an entry receptor in dendritic cells and macrophages (Rappocciolo, 2006
#1195), and neutralization of DC-SIGN was previously shown to inhibit KSHV infection of
activated blood-derived and resting tonsil-derived B lymphocytes [8]. KSHV-gB binds to
DC-SIGN in a dose dependent manner, but this interaction has yet to be deemed essential
for KSHV entry in any cell type [12].
In this study, our primary objectives are to evaluate the role of KSHV-gH in entry
into primary B lymphocytes, and determine whether DC-SIGN is the primary receptor for
KSHV in B lymphocytes as has been previously reported [8]. Finally, we seek to examine
whether either factor (DC-SIGN as a receptor and KSHV-gH as a glycoprotein) dictates the
susceptibility of any specific B cell subsets to KSHV infection. Our results demonstrate that
both DC-SIGN and gH are dispensable for infection of tonsil-derived B lymphocytes and
suppression of these factors does not substantially alter KSHV tropism in B lymphocytes.
Interestingly, by working with these two factors in combination, we are able to establish
that KSHV has two mechanisms for entry into the centrocyte subset: one dependent on gH
and the other dependent on DC-SIGN. Taken together, our results reveal that mechanisms
of KSHV entry into B lymphocytes are complex, multi-factoral and subset-specific.
2. Materials and Methods
2.1. Preparation of Cell-Free Recombinant KSHV Virions
iSLK cell lines harboring BAC16-KSHV-WT-eGFP [13] and BAC16-KSHV-∆gH-eGFP [6]
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10%
Cosmic Calf Serum (CCS), PSG, puromycin (1 µM), G418 (250 µg/mL), and hygromycin
(1.2 mg/mL) at 37 ◦C in 5% CO2. For virus preparations, 12 × T185 flasks at 80–90%
confluence were stimulated for 72 h with 3 mM sodium Butyrate and 2 µM doxycycline
hyclate. At 3 days post induction, supernatants were clarified by centrifugation at 1700 rpm
for 12 min at 4 ◦C and filtered with a 0.45 µm vacuum filter. Virions were pelleted out of
clarified supernatant over 25% sucrose in TNE (50 mM Tris [pH 7.4], 100 mM NaCl, 0.1 mM
EDTA, pH 7.4) by centrifugation at 22,000 rpm for 2 h. Virus pellets were resuspended
in 2 mL TNE and stored at −80 ◦C. Infectious titer doses were determined for iSLK-
BAC16-KSHV-WT-eGFP by serial dilution infection on human fibroblasts and quantified
at 3 days post infection via flow cytometry. Infectious titer doses were determined for
iSLK-BAC16-KSHV-∆gH-eGFP by calculating equal genome copy number to that of iSLK-
BAC16-KSHV-WT-eGFP via quantitative PCR (qPCR).
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2.2. Isolation of Primary Lymphocytes from Human Tonsil
De-identified human tonsil specimens were obtained from the National Disease Re-
search Interchange (NDRI) following routine tonsillectomies. Less than 24 h post-surgery,
tonsil specimens were shipped and delivered in DMEM+PSG to the laboratory. Primary
lymphocytes were extracted via dissection and maceration of tonsil tissues in RPMI media.
Lymphocyte-containing media were passed through a 40 µm filter, and pelleted at 1500 rpm
for 5 min. Red blood cell lysing solution (0.15 M ammonium chloride, 10 mM potassium
bicarbonate, 0.1 M EDTA) was utilized to lyse red blood cells present in the lymphocyte
preparation. Following 3 min of RBC lysis, lymphocytes were diluted in 50 mL of PBS,
manually counted and pelleted at 1500 rpm for 5 min. Aliquots of 1 × 108 cells were
resuspended in 1 mL of freezing media (90% FBS, 10% DMSO) and cryopreserved.
2.3. Isolation and KSHV Infection of Total B lymphocytes
Tonsil primary lymphocyte suspensions were thawed at 37 ◦C, slowly diluted to 5 mL
with RPMI, and pelleted at 1500 rpm for 5 min. Pellets were resuspended in 1 mL RPMI
with 20% FBS, 100 µg/mL DNase I, and 100 µg/mL Primocin. Cells were maintained in a
low-binding 24 well plate at 37 ◦C and 5% CO2 incubator for two hours. After recovery,
total lymphocytes were counted and total B cells were isolated using Mojosort™ Human
Pan B cell isolation kit (Biolegend 480082) according to manufacturer’s instructions. Bound
cells that were non-B cells were retained and maintained in 1 mL RPMI, 20% FBS at 37 ◦C
and 5% CO2 incubator.
Recombinant KSHV virion preparations were titrated on human fibroblasts and an
ID20 was calculated by linear regression. The equivalent ID20 dose from fibroblasts
(in µL/cell) was diluted in serum free RPMI media and used to infect 1 million B cells.
For experiments including KSHV-∆gH, the WT virus was used at ID20 doses as described
above, and KSHV-∆gH was used at an equivalent genome dose based on the WT stock. In
all experiments, Mock-infected cultures were included as an internal reference for the GFP
positive signal and to allow analysis of culture-specific effects. B cells in infection media
were spinoculated at 1000 rpm for 30 min at 4 ◦C in 12 × 75 mm round bottom tubes. After
spinoculation, tubes were incubated at 37 ◦C for an additional 30 min. After incubation,
infected cultures were transferred to X-ray irradiated CDW32 L cells in a 48 well plate and
reconstituted with 20% fetal bovine serum, 100 µg/mL of Primocin and 1 million cells from
the bound fraction of the B cell isolation for a final concentration of 4 million cells/mL.
Reconstituted lymphocyte cultures were incubated at 37 ◦C, 5% CO2 for the duration of
the experiment.
2.4. DC-SIGN Neutralization
Total B lymphocytes were isolated as in 2.3 and were incubated with Human DC-
SIGN/CD209 Antibody [anti-DC-SIGN mAb] (R&D systems MAB161-100) at varying
concentrations (0 µg/mL, 2.5 µg/mL, 5 µg/mL) for 30 min on ice prior to infection as
described above.
2.5. DC-SIGN Depletion
Total B lymphocytes were isolated as described above, and were further separated
into DC-SIGN+ (bound) and DC-SIGN- (unbound) fractions using CD209 (DC-SIGN)
MicroBeads (Miltenyi 130-092-868) according to manufacturer’s instructions. Following
separation, half of the DC-SIGN- B cells were reconstituted with DC-SIGN+ B cell frac-
tion and the remaining cultures remained depleted. These depleted and reconstituted
samples were Mock-infected or infected with KSHV-WT and KSHV-∆gH and cultured as
described above.
2.6. Flow Cytometry Analysis
At day 0 (baseline) or at 3 days post-infection (3 dpi), 5 × 105 lymphocytes were
aliquoted into a 96-well round bottom plate and pelleted at 1500 rpm for 5 min. Resuspen-
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sion of the pellet was performed with 100 µL PBS containing zombie violet fixable viability
stain (Biolegend Cat# 423113) and incubated on ice for 15 min. After incubation, 100 µL
PBS, containing 2% FBS and 0.5% BSA and 0.1% sodium azide (FACS Block) was added to
the wells. Cells were pelleted at 1500 rpm for 5 min and resuspended in 200 µL FACS Block
followed by a 10 min incubation on ice. Cells were pelleted at 1500 rpm for 5 min and
resuspended in 50 µL of PBS containing 0.5% BSA and 0.1% sodium azide (FACS Wash),
10 µL BD Brilliant Stain Buffer Plus (BD 566385) and antibodies as follows: IgD-BUV395
(2.5 µL/test BD 563823), CD77-BV510 (2.0 µL/test BD 563630), CD138-BV650 (2 µL/test BD
555462), CD27-BV750 (2 µL/test BD 563328), CD19-PerCPCy5.5 (2.0 µL/test BD 561295),
CD38-APC (10 µL/test BD 560158), CD20-APCH7 (2 µL/test BL 302313), and DC-SIGN-
PE-Cy7 (2 µL/test BD 330114) and incubated on ice for 15 min. After incubation, 150 µL
FACS Wash was added. Cells were pelleted at 1500 rpm for 5 min followed by two washes
with FACS Wash. Cells were collected in 200 µL FACS Wash for flow cytometry analysis.
Sample data and appropriate compensation controls were acquired on a BD Fortessa X20
flow cytometer and analyzed using FlowJo Software.
2.7. RT-PCR Analysis for Viral Transcripts
At 3 days post infection, 2 × 106 lymphocytes were harvested into Trizol and an equal
volume of DNA/RNA shield (Zymo Research R110-250, Irvine, CA, USA) was added.
RNA extraction was performed using Zymo Directzol Microprep (Zymo Research R2060)
according to manufacturer instructions. RNA was eluted in 10 µL H2O containing 2U
RNase inhibitors and a second DNase step was performed for 30 min using the Turbo
DNA-Free kit (Invitrogen AM1907M, Waltham, MA, USA) according to manufacturer
instructions. Nested RT-PCR amplicon for GAPDH was designed based on NCBI gene id
2597 and LANA and K8.1 assays were designed based on the BAC16 reference sequence
(Genbank MK733609.1) One-step RT-PCR cDNA synthesis and preamplification of GAPDH,
LANA and K8.1 transcripts was performed on 15 ng of total RNA using the Superscript III
One-step RT-PCR kit (ThermoFisher 12574026, Waltham, MA, USA) and 2 µM outer primers
for each target gene (Table 1). Duplicate no RT (NRT) control reactions were assembled
for each sample containing only Platinum Taq DNA polymerase (Thermofisher 15966005)
instead of the Superscript III RT/Taq DNA polymerase mix. After cDNA synthesis at
50 ◦C for 15 min 20 cycles of target pre-amplification was performed with an annealing
temperature of 60 ◦C and 30second extension at 68 ◦C. Then, 2 µL of pre-amplified cDNA or
NRT control reaction was used as template for multiplexed real-time PCR reactions using
TaqProbe 5× qPCR MasterMix -Multiplex (ABM MasterMix-5PM), 5% DMSO, primers at
900 nM and probes at 250 nM against target genes (Table 1) and analyzed using a standard
40 cycle program on a Biorad real time thermocycler. Data is represented as quantitation
cycle (Cq) and assays in which there was no detectable Cq value were set numerically as
Cq = 41 for analysis and data visualization.
Table 1. Primers and probes for the RT-PCR assays used in the study.
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2.8. Statistical Analysis
Data plots and statistical analysis were performed in Rstudio software (version 7.0)
using reshape2 [14], and tidyverse [15] packages. Statistical analysis was performed using
R package: rstatix [16]. Specific statistical tests and the resulting values are described in
detail in the corresponding figure legends.
3. Results
3.1. DC-SIGN Is Widely Expressed among Tonsil B Cell Subsets
We first wanted to establish the subset-specific expression of DC-SIGN in tonsil-
derived B cells prior to infection. This analysis allows us to determine if DC-SIGN expres-
sion correlates with subset-specific susceptibility to KSHV infection and also provides a
baseline for comparison of infected cultures to determine whether our lymphocyte culture
system, or KSHV infection, changes DC-SIGN expression over time. These results reveal
that most tonsil lymphocyte preparations contained 10–15% DC-SIGN+ B cells (Figure 1a).
These results are slightly lower than those previously reported [17]. When we performed
immunophenotypic B cell subset analysis (Table 2, Figure S1) on DC-SIGN positive B cells,
we determined that most B cell subsets, with the exception of MZ-like, were present within
the DC-SIGN+ population and germinal center, naive, and transitional subsets were highly
represented (Figure 1b).
Table 2. Subset definitions for B cell subsets used in this study.
Subset Molecular Markers
Plasma CD19+, CD20+/−, CD138+(Mid to High), CD38−
Transitional CD19+, CD138−, CD38Mid, IgD+ (Mid to High)
Plasmablast CD19+, CD138−, CD38High, IgD+/− (mostly-)
Germinal Center CD19+, CD138−, CD38Mid, IgD−
GC-Centrocytes CD19+, CD138−, CD38Mid, IgD−, CD77−
GC-Centroblasts CD19+, CD138−, CD38Mid, IgD−, CD77+
Naïve CD19+, CD138−, CD38Low, CD27−, IgD+ (Mid to High)
Marginal Zone Like (MZ-Like) CD19+, CD138−, CD38Low, CD27+ (Mid to High), IgD+ (Mid to High)
Memory CD19+, CD138−, CD38Low, CD27+ (Mid to High), IgD−
Double Negative CD19+, CD138−, CD38Low, CD27−, IgD−
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Figure 1. DC-Sign expression in human tonsil with and without KSHV infection. (a) Flow cytometry analysis of DC-SIGN 
expression on the surface of viable B cells in 11 unique tonsil lymphocyte specimens at day 0 (baseline). (b) Analysis as in 
Figure 1. DC-Sign expression in human tonsil with and without KSHV infection. (a) Flow cytometry analysis of DC-SIGN
expression on the surface of viable B cells in 11 unique tonsil lymphocyte specimens at day 0 (baseline). (b) Analysis as in
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(a) showing the distribution of B cell subsets within DC-SIGN+ B cells. Red diamonds indicate the mean of 11 tonsil samples.
(c) DC-SIGN expression at 3 days post-infection (dpi) in Mock-infected and KSHV-infected cultures (left panel, n.s.) or in
KSHV-infected GFP+ B cells (right panel). (d) Frequency of DC-SIGN expression on GFP+ B lymphocytes in KSHV-infected
cultures at 3 dpi. (e) Distribution of B cell subsets within DC-SIGN+ B-cells as in (b) for Mock and KSHV-infected cultures
at 3 dpi (n.s.). Where indicated, data point color scheme indicates unique tonsil specimens and can be compared between
sub-panels within each portion of the figure.
3.2. KSHV Infection Does Not Alter DC-SIGN Expression on B Cells and Expression of DC-SIGN
on KSHV-Infected Cells Is Highly Variable
To determine whether our culture system and/or KSHV infection alters the distribu-
tion of DC-SIGN within B cell subsets, we performed KSHV infection and analysis at 3 dpi
for 10 tonsil lymphocyte preparations quantitating DC-SIGN+ B cells and the distribution of
B cell subsets within the DC-SIGN+ population for both Mock and KSHV-infected cultures.
These results reveal that there was no statistically significant change in overall DC-SIGN
expression on B lymphocytes in Mock vs. KSHV-infected cultures (Figure 1c, left panel).
Moreover, we found that although significant numbers of DC-SIGN+ B cells were present in
KSHV-infected cultures, few of these DC-SIGN+ cells were KSHV infected (as shown by the
expression of the GFP reporter that is constitutively expressed from the recombinant KSHV
genome), indicating that infection is not particularly enriched in the DC-SIGN+ fraction
(Figure 1c, right panel). However, since overall KSHV infection is low in these cultures
(~1% of B cells) we analyzed the data to examine the frequency of DC-SIGN expression on
KSHV-infected (GFP+) cells, specifically (Figure 1d). These data show that the presence
of DC-SIGN in KSHV-infected lymphocytes is highly variable. Finally, we analyzed the
B cell subset distribution for DC-SIGN+ B cells in Mock and KSHV-infected conditions
and found no significant influence of infection on DC-SIGN distribution (Figure 1e). Taken
together, these data show minimal impact of KSHV infection on DC-SIGN expression
and distribution, and indicate that expression of DC-SIGN within infected cells varies
substantially based on donor. Thus, these results do not strongly support or entirely refute
the hypothesis that DC-SIGN is used as an attachment receptor for KSHV infection in
B lymphocytes.
3.3. Neutralization of DC-SIGN Increases KSHV Infection of B Lymphocytes
In order to more directly determine whether DC-SIGN is required for KSHV entry into
B lymphocytes, we performed experiments in which we blocked DC-SIGN using increasing
concentrations of a DC-SIGN neutralizing antibody prior to infection and assessed the
magnitude and distribution of KSHV infection at 3 dpi. Surprisingly, these results revealed
increased KSHV infection at 3 dpi in most samples (Figure 2a). In order to account for the
variable susceptibility of tonsil samples to KSHV infection in our model [5], we analyzed
these data as a change in GFP using controls with no antibody treatment as a normalization
factor. In this analysis we can clearly see that the majority of tonsils included in this analysis
show increased infection in response to DC-SIGN neutralization, and the difference was
statistically significant (p = 0.02) at the 5 µg/mL dose (Figure 2b).
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Figure 2. Effect of DC-SIGN neutralization on KSHV infection in tonsil B lymphocytes. (a) Flow cytometry analysis of KSHV infec-
tion of 10 unique tonsil specimens based on GFP+ B lymphocytes at 3 dpi with indicated doses of DC-SIGN neutralizing antibody 
(n.s.) (b) analysis as in (a) normalized within samples to the 0µg/mL dose in order to remove between-sample variability. p = 0.02 
comparing 0 µg/mL to 5 µg/mL using Student’s T-test with Holm correction for multiple comparisons. (c) Flow cytometry analysis 
of plasma cell frequencies at 3dpi with indicated doses of DC-SIGN neutralizing antibody in Mock and KSHV-infected conditions. 
Two-way repeated measures ANOVA analysis reveals a statistically significant influence of mAb treatment on PC frequency (p = 
0.003, F = 8.3) (d) normalized analysis of subset targeting by KSHV (treatment-control) for indicated doses of DC-SIGN neutralizing 
antibody (n.s.) (e) Normalized correlation analysis showing linear relationships (Pearson’s correlation coefficient) comparing the 
change in frequency of GFP within B cell subsets and the change in overall GFP frequency at 5 µg/mL neutralizing antibody dose. 
Power analysis indicates with this sample number correlations with r ≥ 0.77 are statistically significant. (f) replicate infections as in 
(a) with or without DC-SIGN neutralizing antibody at 5 µg/ml were harvested into trizol at 3 dpi and RT-PCR analysis was per-
formed for GAPDH (human housekeeping gene), LANA (viral latent) and K8.1 (viral lytic) transcripts. No-RT control reactions 
were used to validate that DNA was not the source of amplification. Viral target Cq values were normalized to internal GAPDH 
controls and red diamonds indicate means of 8 unique tonsil specimens with two technical replicates per target. (n.s.). 
Figure 2. Effect of DC-SIGN neutralization on KSHV infection in tonsil B lymphocytes. (a) Flow cytometry analysis of KSHV
infection of 10 unique tonsil specimens based on GFP+ B lymphocytes at 3 dpi with indicated doses of DC-SIGN neutralizing
antibody (n.s.) (b) analysis as in (a) normalized within samples to the 0µg/mL dose in order to remove between-sample
vari bility. p = 0.02 comparing 0 µg/mL to 5 µg/mL using Student’s T-test with Holm correction for multiple comparisons.
(c) Flow cytometry analysis of plasma cell frequencies at 3dpi with indicated doses of DC-SIGN neutralizing antibody
in Mock and KSHV-infected conditions. Two-way repeated measures ANOVA analysis reveals a statistically significant
influence of mAb treatment on PC frequency (p = 0.003, F = 8.3) (d) normalized analysis of subset targeting by KSHV
(treatment-control) for indicated doses of DC-SIGN neutralizing antibody (n.s.) (e) Normalized correlation analysis showing
linear relationships (Pearso ’s correlatio coefficient) co paring the change in frequency of GFP within B cell sub ets and
the change in overall GFP frequency at 5 µg/mL neutralizing antibody dose. Power analysis indicates with this sample
number correlations with r ≥ 0.77 are statistically significant. (f) replicate infections as in (a) with or without DC-SIGN
neutralizing antibody at 5 µg/mL were harvested into trizol at 3 dpi and RT-PCR analysis was performed for GAPDH
(human housekeeping gene), LANA (viral latent) and K8.1 (viral lytic) transcripts. No-RT control reactions were used to
validate that DNA was not the source of amplification. Viral target Cq values were normalized to internal GAPDH controls
and red diamonds indicate means of 8 unique tonsil specimens with two technical replicates per target. (n.s.).
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In order to determine whether the increase in GFP+ B cells with DC-SIGN neutraliza-
tion was due to increased frequency or targeting of a specific B cell subtype, we performed
subset analysis on these samples. Analysis of overall subset frequencies (infected and unin-
fected) in these cultures at 3 dpi revealed that most subsets did not change with DC-SIGN
neutralization in either the Mock or KSHV-infected conditions (Figure S2). However, we
did observe a statistically significant increase in the CD138+ plasma cell population at
the 5 µg/mL dose only in the KSHV-infected conditions (Figure 2c). This observation is
particularly interesting given our recent publication showing that plasma cells are highly
targeted by KSHV early in infection [5].
Next, we wanted to determine whether neutralization of DC-SIGN influences the
distribution of KSHV infection within B cell subsets. In these experiments, if a particular
subset shows decreased targeting by KSHV in the presence of DC-SIGN neutralization,
we can conclude that DC-SIGN is important for viral entry in that cell type. Our results
show no statistically significant increase or decrease in KSHV infection of any specific B
cell subset. However, infection of memory, MZ-like and naive B cells was increased in most
of the samples (Figure 2d). These results, therefore, do not identify any B cell subset in
which DC-SIGN is critical for entry.
We next wanted to determine whether increased the overall infection we observed
with DC-SIGN neutralization (Figure 2b) was correlated with changes in infection of any B
cell subsets. In order to examine this, we plotted the change in frequency of GFP within B
cell subsets against overall change in GFP frequency at the 5µg/mL neutralizing antibody
dose and calculated correlation coefficients via the Pearson method (Figure 2e). Although
power analysis indicates that these correlations are not strong enough to be statistically
significant with this sample number, we observe that samples with increased GFP also
displayed increased proportions of infected plasma, MZ-like and memory B cell subsets.
These observations indicate that these particular subsets do not depend upon DC-SIGN
for KSHV entry. We hypothesized that DC-SIGN neutralization was increasing overall
infection by increasing targeting of B cell subsets that undergo lytic replication, thereby
acting as a point of expansion for the virus. To test this hypothesis, we performed RT-PCR
analysis for LANA (a latent gene) and K8.1 (a lytic gene) on eight unique tonsil specimens
with and without DC-SIGN neutralization at 5 µg/mL. These results show that there
is no difference in lytic gene expression between untreated cultures and cultures treated
withDC-SIGN neutralizing antibodies (Figure 2f). These results suggest that the mechanism
for increased infection with DC-SIGN neutralization is not increased viral spread within
the cultures.
3.4. KSHV gH Is not Required for KSHV Infection of Tonsil Derived B Lymphocytes
We recently showed that a mutant KSHV virus lacking gH, is globally defective for
entry into adherent cell lines including epithelial, endothelial and fibroblast cell lines but
was still able to infect the MC116 lymphoma cell line [6]. These results suggest that gH
may be dispensable for entry into B cells. In order to test this hypothesis in our primary
tonsil lymphocyte system, we utilized the same mutant virus that was constructed for this
previous study (KSHV-∆gH). We performed infections with 7 unique tonsil lymphocyte
samples using KSHV-WT, KSHV-∆gH and Mock infection as described above, and assessed
the distribution of KSHV infection at 3 dpi using flow cytometry. It should be noted
that because KSHV-∆gH cannot infect fibroblasts we cannot use our normal system for
functional titration of the virus stock to normalize infection. Thus, for these experiments we
performed titration of the KSHV-WT stock as usual on fibroblasts to determine the optimal
infectious dose, and then used genome quantitation of both KSHV-WT and KSHV-∆gH
virus stocks in order to calculate an equivalent genome dose for KSHV-∆gH. These results
reveal that KSHV-∆gH infects tonsil-derived B cells at levels comparable to those seen
with KSHV-WT. Interestingly, four of seven tonsil samples showed higher levels of GFP+
B lymphocytes in KSHV-∆gH compared to WT (Figure 3a). We wanted to determine
whether the difference in infection efficiency with KSHV-WT vs. KSHV-∆gH was related
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to the levels of B cell subsets in the tonsil samples at the time of infection. To do this
analysis, we calculated the difference between the percent of GFP+ B cells with each virus
on a per-sample basis (KSHV-∆gH minus KSHV-WT) and compared this value to the
sample-specific baseline frequency of each B cell subset. These data reveal that KSHV-∆gH
infectivity is highly correlated with baseline levels of double negative B cells (an atypical
memory B cell subtype), but that KSHV-∆gH had lower infectivity in samples with high
levels of transitional B cells (Figure 3b). These results may suggest that KSHV infection of
transitional B cells relies more heavily upon gH-dependent entry mechanisms compared to
entry into double negative B cells. When we examined the distribution of GFP within B cell
subsets at 3 dpi for these experiments, we found that there was no significant difference
in B cell targeting between KSHV-WT and KSHV-∆gH (Figure 3c). Finally, we wanted to
determine whether the distribution of B cell subsets within the infected (GFP+) fraction
was different between KSHV-WT and KSHV-∆gH. This analysis showed that there was
also no significant difference between KSHV-WT and KSHV-∆gH infection (Figure 3d).
Thus, neither the amount of infection within any B cell subset nor the proportion of B cell
subsets within the infected fraction differed between KSHV-WT and KSHV-∆gH. Taken
together, these results indicate that KSHV-∆gH (a virus which is globally defective in non-B
cell types) can infect primary B cells, and displays similar infectivity and B cell subset
tropism when compared to KSHV-WT. We would conclude from these data that overall
susceptibility of individual tonsil specimens to infection with KSHV-∆gH is dependent
upon the B cell composition of the specimen, suggesting that gH does play a role in entry
into B lymphocytes. However, gH is not strictly required for KSHV entry into any B cell
subset, suggesting that this glycoprotein does not play a pivotal role in KSHV infection of
B lymphocytes in human tonsil.
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(Pearson’s correlation coefficient) between baseline frequency of B-cell subsets and the change in GFP between KSHV-∆gH
and KSHV-WT on a per-sample basis. Power analysis indicates with this sample number correlations with r ≥ 0.86 are
statistically significant. (c) Distribution of KSHV-WT and KSHV-∆gH infected cells (GFP+) within B cell subsets at 3 dpi
(n.s.) (d) Distribution of B-cell subsets within infected (GFP+) fraction for KSHV-WT and KSHV-∆gH. Red diamonds
indicate mean for each condition (n.s.). Where indicated, data point color scheme indicates unique tonsil specimens and can
be compared between sub-panels within each portion of the figure.
3.5. Depletion of DC-SIGN in KSHV-WT and KSHV-∆gH Infections Reveals Multiple, Entry
Mechanisms for KSHV in Tonsil B Lymphocytes
In order to examine whether KSHV-∆gH interacts with DC-SIGN to enter into B
lymphocytes and to validate our earlier DC-SIGN neutralization data (Figure 2) via another
method, we performed experiments with 6 unique tonsil specimens where we isolated
total B lymphocytes and performed a second step where we separated DC-SIGN+ and
DC-SIGN- B cells. Because DC-SIGN+ cells represent a minor population in tonsil B cells
(Figure 1a) we did not have sufficient cell numbers to infect the populations separately.
Therefore, we adopted a strategy where we either infected DC-SIGN-depleted populations
or reconstituted the depleted population with DC-SIGN+ B cells prior to infection. Analysis
of KSHV infection in these cultures revealed that KSHV-WT infection is uniformly higher
in DC-SIGN reconstituted cultures compared to DC-SIGN depleted cultures. This trend
was similar in KSHV-∆gH infected cultures with the exception of one tonsil sample in
which infection was increased in reconstituted culture for KSHV-WT and decreased in the
same condition with KSHV-∆gH (Figure 4a). Next, we examined the distribution of GFP
within B cell subsets for DC-SIGN depleted vs. reconstituted cultures in order to determine
whether DC-SIGN is required for entry into any particular B cell subset. Consistent with
our neutralization data, depletion of DC-SIGN did not abolish infection of any B cell
subsets with KSHV-WT. Consistent with our previous analysis (Figure 3) there was no
statistically significant difference in infection comparing WT to ∆gH for either depleted
or reconstituted fractions. For KSHV-WT, although infection of most subsets tended to be
higher in the reconstituted fractions, there was no significant difference between DC-SIGN
depleted and reconstituted cultures for any subset with KSHV-WT. Results were similar
for KSHV-∆gH with the exception of centrocytes (the CD77 negative sub-population of
germinal center B cells) where infection was absent in the DC-SIGN depleted culture
vs. the DC-SIGN reconstituted culture (p = 0.03) (Figure 4b). These results support our
previous conclusions that DC-SIGN plays a minor role as a receptor for KSHV entry into
tonsil-derived B cells, and that the KSHV glycoprotein gH is not required for entry into any
B cell subsets. However, our data reveal that in the absence of both the DC-SIGN receptor
and the gH glycoprotein, KSHV cannot infect centrocytes. This implies that KSHV has
only two entry mechanisms for centrocytes: (1) a gH-dependent mechanism that uses a
receptor other than DC-SIGN, and (2) a gH-independent mechanism that uses DC-SIGN as
the receptor. In KSHV-WT, both entry mechanisms are functional and no difference is seen
when DC-SIGN is depleted because the gH-dependent entry mechanism is intact. When
gH is absent but DC-SIGN is present (KSHV-∆gH reconstituted) entry into centrocytes is
mediated by the interaction of another KSHV-gp and DC-SIGN. When gH is absent and
DC-SIGN is absent, KSHV has no entry mechanism for centrocytes (Figure 4c).
Taken together, our examination of the roles of KSHV-gH and cellular DC-SIGN
reveals that:
1. KSHV-gH is not required for entry into tonsil-derived B lymphocytes.
2. KSHV-gH can participate in KSHV entry into centrocytes via a DC-SIGN independent
entry mechanism.
3. DC-SIGN is not necessary for KSHV entry into any B cell subset.
4. DC-SIGN does play a role in KSHV entry into tonsil-derived B cells, but in all B-cell
subtypes alternative entry mechanisms exist.
Our results presented in this study provide a first glimpse into the complexity of
KSHV entry in the lymphocyte compartment and highlight that multiple subset-dependent
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entry mechanisms are employed by KSHV which depend upon multiple cellular receptors
and multiple KSHV glycoproteins. Further studies are needed to establish the roles of
additional receptor-gp interactions in these important cell types in order to rationally
design therapies and vaccine strategies that will effectively limit KSHV entry into, and
spread within, the human immune system.
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sis of 6 unique tonsil specimens in which DC-SIGN+ cells were depleted, or depleted fractions were reconstituted with isolated DC-
SIGN+ B cells prior to KSHV infection with KSHV-WT or KSHV-∆gH and analyzed 3 days post infection (n.s.) (b) analysis as in (a) 
showing distribution of infected (GFP+) cells within B-cell subsets. * p = 0.03 for depleted vs. reconstituted within KSHV-∆gH infec-
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analysis of 6 unique tonsil specimens in which DC-SIGN+ cells were depleted, or depleted fractions were reconstituted
with isolated DC-SIGN+ B cells prior to KSHV infection with KSHV-WT or KSHV-∆gH and analyzed 3 days post infection
(n.s.) (b) analysis as in (a) showing distribution of infected (GFP+) cells within B-cell subsets. * p = 0.03 for depleted vs.
reconstituted within KSHV-∆gH infection of centrocytes (c) Model for entry mechanisms in the presence and absence of
DC-SIGN and/or ∆gH for centrocytes.
4. Discussion
Our results presented in this study indicate that KSHV can use DC-SIGN as an at-
tachment/entry factor, but DC-SIGN is not required for entry into any B cell subsets.
In particular, depletion of DC-SIGN-expressing B cells had a more profound effect than
antibody-mediated neutralization of DC-SIGN. Indeed, KSHV infection was overall in-
creased in our neutralization experiments. These results contrast significantly with the only
previous study to perform an in-depth analysis on the role of DC-SIGN as an entry receptor
for KSHV, which was performed by Rappocciolo et al. in 2008 [8]. This particular study
utilized both unstimulated tonsil-derived B cells and peripheral blood B-cells that were
activated with CD40 ligand (CD40L) and interleukin 4 (IL-4) as target cells and wild-type
KSHV virions derived from BCBL-1 PEL cells as virus inoculum. In our results, we show a
lower percentage of DC-SIGN+ B cells compared to this previous study possibly indicating
that our tonsil B cells are less activated. One reason for this discrepancy may be method-
ological. We avoid using Ficoll-Hypaque and similar agents for lymphocyte purification
and we utilize negative selection strategies for B cell isolation in order to avoid aberrant
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activation of cells in our system. Importantly, we utilized multi-color flow cytometry
for our analysis method which allows us to see KSHV infection using the constitutively
expressed GFP reporter present in the BAC16 genome (which we have previously shown
is a reliable marker for KSHV tropism [5]) alongside surface antigen markers for B cell
subsets. These techniques were distinct from the previous study which analyzed B cells as
a single population and utilized virus detection methods that were biased towards lytic
replication as opposed to quantitating infected cell numbers.
When we employed a neutralizing antibody to disrupt any interaction between DC-
SIGN and KSHV glycoproteins, we observed significantly increased KSHV infection at
the highest dose (5 µg/mL), which was also the optimal dose for inhibition of DC-SIGN -
ICAM3 interaction during characterization of the neutralizing antibody by the manufac-
turer. These results differ from those reported in Rappocciolo et al., where use of the same
anti-DC-SIGN neutralizing antibody clone but at much higher concentrations (20 µg/mL)
effectively blocked KSHV infection of activated peripheral B-cells [8]. Aside from the
differing mAb concentrations, our culture model recapitulates the total tonsil lymphocyte
environment after infection. Thus, we might hypothesize this mAb enhancement effect
may be mediated by activation of DC-SIGN signaling altering other attachment factors
or via altered interactions involving non-B cells in the culture model. Our analysis of the
distribution of KSHV infection within B-cell subsets did not reveal any change in KSHV
targeting of B-cells with DC-SIGN neutralization, and RT-PCR results show no increase
in lytic replication in culture where the neutralizing antibody was used. Thus, our data
provide no evidence that the increase in overall infection with DC-SIGN neutralization is
a result of altered KSHV targeting or spread. We did observe an increase in total plasma
cell numbers in DC-SIGN neutralized, KSHV-infected lymphocyte cultures. Our previous
work has shown that our lymphocyte culture system does not favor the survival of plasma
cells, but KSHV infection increases overall plasma cell numbers at 3 dpi [5]. Recently,
activation of DC-SIGN signaling via antibody binding was shown to promote survival
of B lymphoma cells [18]. Thus, the combination of DC-SIGN neutralization and KSHV
infection may synergistically promote the survival of plasma cells in our culture system,
and we speculate that the presence of plasma cells promotes KSHV infection via unknown
mechanisms that are possibly related to the cytokine milieu. Overall, our results collectively
show that DC-SIGN is not required for KSHV entry into any B-cell subset.
To date, it is unknown which viral glycoproteins are essential for KSHV entry in tonsil
derived B lymphocytes, and this gap in our understanding limits the rational design of
vaccines designed to limit the ability of KSHV to invade the immune system. We recently
showed that gH is essential for KSHV entry into epithelial cells, endothelial cells and
fibroblasts but is not required for entry into the MC116 B-cell lymphoma cell line [6].
Our current study extends these findings and shows that gH is also not required for
entry into primary tonsil lymphocytes. Interestingly, our results revealed tonsil donor-
specific differences in the infectivity of KSHV-∆gH compared to KSHV-WT, and that
these differences are correlated to the frequencies of transitional and double negative B
cells in the original tonsil sample. These results provide a critical insight indicating that
vaccination strategies concentrated on KSHV-gH may leave the immune system vulnerable
to infection. However, our DC-SIGN depletion experiments show that there is a gH-
dependent mechanism for KSHV entry into centrocytes. Thus, although gH is not strictly
required for entry into any B cell type, gH-dependent entry mechanisms do exist for tonsil-
derived B cells. Taken together, our results indicate that KSHV entry in B lymphocytes is
complex, multi-factoral and that subset-dependent entry mechanisms exist but, in all cases,
KSHV has multiple entry points to exploit on any given B cell subset.
Our study does have some limitations that require further research. In particular, for
the neutralization experiment we chose to utilize a neutralizing antibody that may not
be optimal for the inhibition of DC-SIGN and KSHV glycoprotein interactions. The anti-
DC-SIGN antibody we utilized is optimized to neutralize the interaction of DC-SIGN with
ICAM-3/CD50. It should be noted that the DC-SIGN receptor is a tetramer protein com-
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posed of four individual domains: the C-terminal carbohydrate recognition domain (CRD),
the neck-repeat region, the transmembrane domain, and the N terminal cytoplasmic tail.
Due to DC-SIGN’s role in the process of viral infection and its structural complexity, many
groups believe that blocking the sugar binding site, ICAM-3 epitope in the carbohydrate
recognition domain (CRD) will overall inhibit DC-SIGN and not allow the virus to enter.
This assumption is believed to be true because the ICAM-3 epitope is located in the center
of the carbohydrate recognition domain where most molecular processes are mediated
in the DC-SIGN receptor [19]. Importantly, the biochemistry of any interactions between
DC-SIGN and KSHV glycoproteins has not been established. The fact that our results
show increased infection with DC-SIGN neutralization could imply that the neutralizing
antibody may be binding to a different epitope on DC-SIGN and that the antibody is not
neutralizing the actual interaction of the viral glycoproteins to DC-SIGN. More research is
needed to decipher the real interactions between DC-SIGN and KSHV glycoproteins to be
able to fully neutralize those specific interactions. Moreover, our results with DC-SIGN
neutralization highlight the need to better establish the role of DC-SIGN signaling in our
tonsil lymphocyte cultures and its impact on KSHV infection.
Future studies are also needed to determine if the other conserved glycoproteins: gB,
gM, gN, ORF4 and gpK8.1 are essential for KSHV entry in tonsil lymphocytes. Through
such studies, we will have the opportunity to unravel different entry mechanisms for
KSHV in tonsil derived B cells and to determine what viral glycoproteins are essential for
entry. In addition, future studies are needed to determine the specific cellular receptors
that KSHV uses to enter each susceptible B cell subset and how these receptors change
based on inflammatory and metabolic factors that may influence the spread of KSHV
within a human host. Previous studies have shown that cellular receptors for KSHV can
be modulated by metabolic factors such as high glucose associated with diabetes [20].
Moreover, KSHV replication has been shown to modify metabolic parameters such as
lipogenesis [21], creating a positive feedback loop between viral spread, persistence and
pathogenesis. Understanding the fundamental virology of KSHV entry in the lymphocyte
compartment will be essential to rationally designing treatment strategies that limit KSHV
spread and pathogenesis within a human host. Moreover, the rational design of vaccines to
prevent the person-to-person spread of KSHV, and thereby limit the public health impact
of KSHV-associated malignancies, will depend upon our understanding of how KSHV
invades the immunological compartment. The results presented herein represent a critical
first step in filling this critical gap in our understanding of KSHV virology.
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